Alkermes Plc at TD Cowen Healthcare Conference Transcript
All right. I think we're going to go ahead and get started. Just on track but thank you everyone for joining us in the room and online today for the 2026 TD Cowen Healthcare conference. And I'm Joe Thome, one of the senior biotech analysts here on the team at TD Cowen, and it's my pleasure to have with me today, Chairman and CEO of Alkermes, Richard Pops. So thank you for joining us.
Obviously, it's been a busy year and busy start to 2026 with closing the election. Maybe if you wanted to start with a quick state of the business, and what investors should be looking for 2026, and then we can dive into the individual parts.
Well, good morning. Good to see you, too. So 2025 was just jam packed with changes at the company. And in fact, in many ways it perfected this transition we've made of the company over many years. And a lot of it happened in the third and fourth quarter. And one of the things we've been doing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
